Plexision Inc

Special Pathogens Laboratory is a leading provider of evidence-based solutions for detecting, controlling, and remediating Legionella and other waterborne pathogens. With a multidisciplinary team of experts in microbiology, engineering, infectious disease, public health, and communication, they deliver reliable results, outbreak prevention, and help mitigate liability. Their services include proactive routine monitoring for Legionella and waterborne pathogens, total Legionella control and remediation strategies, and education to empower individuals and organizations to make evidence-based decisions for disease prevention. Led by Dr. Janet E. Stout, an internationally renowned infectious disease microbiologist with over 30 years of pioneering research in Legionella control and prevention, Special Pathogens Laboratory is dedicated to providing accurate and effective water management solutions.Generated from the website

Promethean Life Sciences, based in Pittsburgh, PA, specializes in creating innovative allograft skin products designed for the healing of chronic and traumatic wounds, as well as for reconstructive surgery applications. Their offerings, such as GammaGraft and Repriza, provide cost-effective solutions that are sterile, shelf-stable, and support tissue ingrowth and healing. The company is committed to advancing medical technology and is actively developing a wider range of medical products. Promethean Life Sciences aims to partner with healthcare providers to enhance patient care and outcomes through their advanced graft solutions. Generated from the website

Vivasc Therapeutics Inc., based in Pittsburgh, PA, specializes in innovative drug delivery systems focused on reversing the effects of heart failure and treating atrial fibrillation. Utilizing their proprietary Cardiac Targeting Peptide, they aim to deliver therapeutic agents specifically to cardiomyocytes, addressing underlying cellular dysfunction rather than merely alleviating symptoms associated with heart diseases. Founded in 2020, the company has engaged in several STTR Phase I projects, demonstrating significant advancements in delivery methods for treatment options like miRNA and amiodarone, designed to target heart tissues with precision. Their research holds promise for improving patient outcomes by mitigating adverse effects commonly related to current heart failure and arrhythmia treatments. Generated from the website